Lv1
38 积分 2022-10-18 加入
From covalent to reversible: the expanding role of BTK inhibitors in chronic lymphocytic leukemia
4天前
已完结
Advances in targeted and cellular therapies for relapsed/refractory mantle cell lymphoma: immunotherapeutic strategies and challenges
4天前
已完结
Mapping the epidemiology of cancer-related anemia: A systematic scoping review of global prevalence and incidence
5天前
已完结
Roadmap for developing MRD as an early endpoint for drug approval in lymphoma
1个月前
已完结
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
1个月前
已完结
Ramantamig (JNJ-79635322), a novel T-cell-engaging trispecific antibody targeting BCMA, GPRC5D, and CD3, in multiple myeloma models
1个月前
已完结
Challenges facing CAR T-cell immunotherapy in multiple myeloma
1个月前
已完结
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
1个月前
已完结
Elranatamab in Relapsed/Refractory Multiple Myeloma: Mechanisms, Clinical Evidence, and Emerging Perspectives
1个月前
已完结
Isatuximab: an anti-CD38 therapy that addresses unmet needs and mechanisms of resistance in multiple myeloma
1个月前
已完结
皖公网安备34019202002308
